Anandamide-Induced Neuroprotection of Cortical Neurons Relies on Metabolic/Redox Regulation and Mitochondrial Dynamics
Programa de Posgrado (Doctorado) en Ciencias Biológicas, Universidad Nacional Autónoma de México, 04510 Mexico City, Mexico
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Investigación en Neuroquímica (IUIN), Universidad Complutense, 28040 Madrid, Spain
Instituto de Investigaciones Sanitarias Ramón y Cajal y Centro de Investigaciones en Red Enfermedades Neurodegenerativas, Madrid, Spain
Department of Cardio-Renal Physiopathology, Instituto de Cardiología Ignacio Chávez, 14080 Mexico City, Mexico
Laboratorio F-315, Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, 04510 Mexico City, Mexico
Laboratorio de Nanotecnología y Nanomedicina, Departamento de Atención a La Salud, Universidad Autónoma Metropolitana-Xochimilco, 04960 Mexico City, Mexico
Subdirección de Oncología y Hematología, Instituto Nacional de Cancerología, 14080 Mexico City, Mexico
Department of Medical Elementology, Peoples Friendship University of Russia, RUDN University), Moscow, 117198 Russia
Center of Bioelementology and Human Ecology, IM Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119146 Russia
Laboratory of Molecular Ecobiomonitoring and Quality Control, Yaroslavl State University, Yaroslavl, 150003 Russia
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461 USA
Facultad de Ciencias, Universidad Nacional Autónoma de México, 04510 Mexico City, Mexico
Abstract
Mitochondrial disruption is a key mechanism in the etiology of neurodegenerative diseases. Promoting mitochondrial dynamics and renewal of the mitochondrial network can restore its function and sustain neuronal viability. Although a growing body of evidence implicates endocannabinoid signaling in the regulation of mitochondrial function, its neuroprotective role in neurodegenerative diseases remains largely unexplored. Clarifying this relationship is crucial for understanding the therapeutic efficacy of the endocannabinoid system. This study aimed to evaluate whether endocannabinoid signaling via PPARγ and CB1 receptors regulates mitochondrial biogenesis and dynamics, exerting neuroprotective actions. Primary cortical neuronal cultures were subject to energy deficiency and excitotoxicity with 3-nitropropionic acid (3NP) and quinolinic acid (QUIN). Neurons were pretreated with the endogenous cannabinoid anandamide (AEA 100 nM), and cell viability and lipid peroxidation levels were characterized. To further explore mitochondrial status, immunofluorescence, western blot, and qPCR of mitochondrial proteins or genes were carried out. The metabolic status was assessed by oxygen consumption and extracellular acidification rates. Intracellular calcium levels and PPARγ transactivation were also analyzed. 3NP + QUIN induced neuronal damage, while AEA treatment afforded a neuroprotective effect. The use of selective receptor antagonists indicated that AEA neuroprotection depends on both PPARγ and CB1 receptors. AEA also increased mitochondrial biogenesis, fission markers and OXPHOS function, while delayed Ca2+ levels and induced PPARγ transactivation. In conclusion, AEA afforded neuroprotection secondary to increased mitochondrial biogenesis and redox regulation triggered by the activation of CB1 and the nuclear receptor PPARγ.
Supplementary Information
The online version contains supplementary material available at 10.1007/s12035-025-05514-z.
Untitled section
Keywords: Endocannabinoid System, Anandamide, PPARγ receptor, Cannabinoid receptors, Energy metabolism, Mitochondrial dynamics
Article notes
Untitled section
Received 2025 May 30; Accepted 2025 Oct 31; Issue date 2026.
Introduction
Neurodegenerative diseases (NDs) are characterized by progressive degeneration of neurons, resulting in irreparable brain damage, and include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). All are characterized by mitochondrial dysfunction as a central pathogenic event that contributes to both the onset and progression of the disease [1]. In NDs, energy deficiency and excitotoxicity interfere with the optimal functioning of neuronal circuits, often culminating in neuronal cell death. Excitotoxicity involves a series of events triggered by persistent glutamate activity and overstimulation of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, leading to an imbalance in Ca2+ homeostasis. Under physiological conditions, mitochondria in the perisynaptic region, particularly in excitatory neurons, internalize calcium to regulate homeostasis; however, under conditions of Ca2+ overload, the mitochondrial membrane potential collapses, leading to energy deficiency, oxidative stress and activation of apoptotic and necrotic cell death pathways [2]. Accordingly, targeting mechanisms of mitochondrial preservation in excitotoxic events could favor the preservation of neuronal integrity in NDs [3].
The central nervous system (CNS) is particularly vulnerable to mitochondrial damage due to its high metabolic activity and the postmitotic nature of neurons, which favors the accumulation of reactive oxygen species (ROS), as often observed in aged brains. Mitochondrial damage and respiratory chain (OXPHOS) dysfunction can originate from ROS-induced mutations of mitochondrial genes (either encoded in mitochondrial and nuclear DNA) or by the aggregation of misfolded proteins that interfere with the functioning of mitochondrial complexes [4]. Neurons are highly polarized cells with a high energy consumption which is met primarily by oxidative phosphorylation of mitochondria, which constantly undergo fusion and fission, altering their morphology and function, metabolic demand, and stress [5]. These dynamic processes are regulated among others by the GTPases, dynamin-related protein 1 (DRP1), which directs fission, and optic atrophy type 1 (OPA1) and mitofusins 1/2 (Mfn1/2), which regulate fusion [6, 7]. In this regard, Peroxisome Proliferator-Activated Receptor Gamma (PPARγ), a nuclear receptor and transcription factor, plays a significant role in regulating neuronal mitochondrial dynamics, as the activation of this receptor increases mitochondrial DNA (mtDNA) expression and ATP levels in in vitro and murine models of NDs [8]. PPARγ activation, and its association with the coactivator PGC1-α, leads to increased mitochondrial biogenesis through coordinated transcription between nuclear and mitochondrial DNA mediated by mitochondrial transcription factor A (TFAM) [9, 10]. In turn, mitochondrial biogenesis improves mitochondrial function and contributes to neuronal survival and protection against NDs. Preclinical studies support the potential use of PPAR-targeted agonists and mitochondrial restoration as an effective treatment for NDs [11, 12].
The Endocannabinoid System (ECS) is a neuromodulatory system that has been widely studied for its neuroprotective potential, mainly through antioxidant and anti-inflammatory mechanisms triggered after the activation of cannabinoid receptor 1 (CB1) [13, 14]. Emerging evidence highlights the mechanistic links between the endocannabinoid system (ECS) and cellular bioenergetics, particularly via the activation of cannabinoid receptor type 1 (CB1), mitochondrial CB1 receptors (mtCB1), and peroxisome proliferator-activated receptors (PPARs) [15]. Endocannabinoids (ECs) are known to modulate the redox balance both under physiological and stress conditions [16]. In addition, cannabinoids upregulate proteins involved in mitochondrial biogenesis and dynamics in a process mediated by PPARγ and CB1 receptors [17–19]. Moreover, the presence of CB1 receptors in mitochondria has emerged as an alternative mechanism for direct regulation of mitochondrial function [20–22]. In this regard, several cannabinoid agonists have been shown to regulate mitochondrial dynamics, mainly phytocannabinoids, though the potential role of ECs cannot be ruled out [23].
Anandamide (N-arachidonoylethanolamine or AEA) is an endogenous cannabinoid agonist that exhibits neuroprotective effects via CB1 activation, regulates the redox neural balance, and exerts mitochondrial modulatory properties, as well as efficacy as a PPARγ receptor agonist [24, 25]. In this regard, the role of mitochondrial dynamics regulation by cannabinoid signaling as a mechanism responsible for its neuroprotective effect has yet to be fully characterized. Therefore, this study aims to evaluate whether stimulation of the ECS by AEA can regulate mitochondrial biogenesis and dynamics through the PPARγ/PGC1α pathway to exert neuroprotective actions in a model of neurodegeneration combining energy deficiency and excitotoxicity in neuronal cells.
Materials and Methods
Cell Culture
Primary neuronal cultures were obtained from the cortex of E14 C57BL/6 mice using the papain dissociation system kit (Worthington-Biochem). The cells were grown in Neurobasal growth medium supplemented with 2% B-27 and plated in culture dishes pretreated overnight with poly-L-lysine. Cells were cultured in 48, 24 or 6 well culture plates and incubated at 37 °C in a 5% CO₂ atmosphere. Experimental procedures were performed in accordance with the guidelines and approval of the Animal Welfare Committees of Universidad Complutense de Madrid, Comunidad de Madrid, the directives of the Spanish Government and the European Commission (RD 118/2021). Animals had unrestricted access to food and water. They were housed (typically, 4–5 mice per cage) under controlled temperature (range, 20–22 °C), humidity (range, 50–55%), inversed light/dark cycle (12 h/12 h) and with environmental enrichment.
Treatments
A model of neurodegeneration combining two of the most relevant characteristics of NDs: excitotoxicity and energy deficiency triggered by mitochondrial damage, was developed. Two neurotoxins were administered to the cultures simultaneously: 3-nitropropionic acid (3NP), described as a selective inhibitor of the mitochondrial enzyme succinate dehydrogenase (SDH, Complex II of the electron transport chain) which promotes oxidative damage and subsequent neuronal death [25], and quinolinic acid (QUIN), an excitotoxin acting in the CNS and agonist of the glutamatergic NMDA-type receptor [26, 27]. Primary neuronal cultures were pretreated 6 h before with 100 nM AEA, this being the lowest effective concentration observed in a dose–response viability assay and then exposed to 3NP (0.5 mM) + QUIN (50 μM) [28–30] for an additional 24 h. The PPARγ receptor antagonist GW9662, and the CB1 antagonist SR141716, were added to the cultures 1 h before receiving the cannabinoid treatments, both at the concentration of 0.5 µM.
Cell Viability Assay
Cell viability was calculated by the conversion of 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) to formazan as an indirect indicator of mitochondrial activity. MTT was prepared in deionized water (1 mg/ml) and 50 µl was added to each well in a 24-well plate. Subsequently, all plates were incubated for 3 h at 37 °C in an atmosphere of 5% CO2. Next, MTT reduction was quantified spectrophotometrically at 595 nm in the iMark microplate ELISA reader (Bio-Rad, Ca, USA). Absorbance data were normalized against cell number for each treatment.
Determination of ATP Levels
The CellTiter-Glo® luminescent cell viability kit was used to quantify the levels of ATP present. For this purpose, 250 μl of CellTiter-Glo® reagent was added directly to cells cultured in 24-well plates with 250 μl of neurobasal medium, and moderately resuspended to promote cell lysis and the release of the ATP present. The plate was incubated for 15 min, considering the same reagent incubation times for each well, and the luminescence was subsequently quantified in a Luminescence Spectrometer Fluostart Omega BMG Labtech.
Lipid Peroxidation Assay
Lipid peroxidation was assessed with the thiobarbituric acid-reactive substances (TBARS) assay, which is based on the colorimetric change caused by the reaction of thiobarbituric acid (TBA) with malondialdehyde, one of the most abundant products of lipid peroxidation. Following cell treatments, homogenates were obtained, 100 μL of TBA reagent was added, and cells were incubated in a water bath at 94 °C for 20 min. Cells were then placed on ice for 5 min and centrifuged. The pellet was discarded, and the supernatants were analyzed for absorbance at 532 nm. A tetramethoxypropane (TMPO) standard curve was prepared, and a linear regression was constructed on this curve to obtain the equation of the straight line, yielding the result in ng of TMPO. These values were correlated with the mg of protein levels quantified for each sample using the Bradford method.
Protein Expression
The key component of mitochondrial and neuronal function, the voltage-dependent anion channel (VDAC), was assessed by western blot analyses. Cell cultures seeded in 6-well plates were homogenized in lysis buffer (25 mM Tris, 50 mM NaCl, 2% Igepal, 0.2% SDS, and protease inhibitors) at pH 7.4. Protein concentration was determined by Bradford analysis [31]. Sixty micrograms of total protein were separated on a polyacrylamide gel (10%) and transferred to PVDF membranes incubated overnight in the presence of primary antibodies. Afterwards, membranes were washed 3 times and incubated for 45 min with the anti-mouse secondary antibody. GAPDH and β-actin were quantified and used as loading controls, upon availability. Immunoblots were performed in triplicate.
Gene Expression
To evaluate whether AEA stimulation directs the expression of genes related to mitochondrial biogenesis in cultures, real time quantitative qPCR was carried out with primers specific to each gene. Total RNA was extracted with Nucleozol (Macherey–Nagel) and following the extraction protocol suggested by the manufacturer. RNA samples (1–2 µg) were subjected to reverse transcription (RT) using the Transcriptor First Strand cDNA Synthesis Kit (Roche Life Science) with random hexamer primers. Real time (RT)-qPCR was performed in 96 or 384-well plates using the LightCycler® Multiplex DNA Master (Roche Life Science) using Fast SYBR Green probe (Applied Biosystems #4,385,610) and appropriate primers in a 7900 HT-Fast (Applied Biosystems). 384 multiwell plates were analyzed in QuantStudio 12 K Flex and QuantStudio 7 Flex, respectively (Applied Biosystems). The 2^(-ΔΔCt) method was utilized to compute the relative expression ratio of the target gene in comparison to the reference gene. Determinations were performed at least in triplicates. A set of GAPDH/actin-specific primers was added to the PCR as control housekeeping genes. Sequences of the primers used are shown in Supplementary Table S.1.
Immunofluorescence
To determine the increase in the number of mitochondria, the expression of the mitochondrial protein ATPβ was evaluated by immunofluorescence. Neurons were cultured on coverslips for 24 h, fixed with 4% paraformaldehyde/PBS for 15 min, and washed three times with PBS. Samples were blocked with 5% BSA for 60 min and permeabilized with PBS-Triton 0.25%. Culture samples were then incubated with or without primary mouse monoclonal antibody against ATPβ (dilution 1:500) and primary rabbit monoclonal antibody against β-tubulin as a neuronal marker (dilution 1:500) in PBS-Triton 0.25% overnight at 4 °C. Samples were then rinsed three times with PBS and incubated with their respective secondary antibody (dilution 1:2000) for 60 min at room temperature, and finally were incubated with DAPI for 15 min. After rinsing, the preparations were mounted and observed under the TCS SP8 laser scanning confocal microscope with Hyvolution super-resolution system, obtaining images of five randomly selected areas of each sample.
MitoTracker Labeling
To label mitochondria, the fluorometric dye MitoTracker RedCMXRos (Thermo Fisher Cat. M7513) [32] was used at a concentration of 200 nM, prepared in complete growth medium and incubated for 15 min at 37 °C after the corresponding treatments. Subsequently, the culture medium was removed, and a careful wash was performed with tempered PBS. Then, cells were fixed with 3.7% formaldehyde in complete growth medium at 37 °C for 15 min and permeabilized in PBS containing 0.2% Triton X-100. The fluorescence was analyzed with a scanning confocal microscope at a wavelength of 579 nM (Carl Zeiss).
Mitochondrial Membrane Potential (ΔΨM) Evaluation
After being treated, neurons were incubated with digitonin (5 μg/ul, 30 min) to permeabilize the cell membrane without altering the properties of the mitochondrial membrane. Subsequently, cells were incubated for 15 min with the fluorescent probe DiSC3 (5) [250 nM] (Cat. 11,520,286, Invitrogen). DiSC3(5), a lipophilic dye that accumulates in hyperpolarized membranes reflecting mitochondrial depolarization [33]. The fluorescence emission was monitored at an excitation wavelength of 635 nm and an emission spectrum of 620 to 700 nm, taking one measurement per second until completing 80 s with the Luminiscence Spectometer SLM-AMINCO.
Calcium Signaling Assay
To measure real time cytosolic calcium concentrations, we used the non-fluorescent Fluo-4 acetoxymethyl ester (Fluo-4 AM; Thermo Fisher Scientific) [34]. Neurons seeded in a 48-well plate were washed with PBS and subsequently incubated for 5 min with 2 µM Fluo-4AM in Hanks’ Balanced Salt Solution (HBSS) without calcium at 37ᵒC in a 5% CO2 atmosphere covered from light. After this time, 5 gentle washes were performed with HBSS medium without calcium. In the last wash, HBSS medium with calcium was added and incubated for an additional 15 min at 37 degrees in a 5% CO2 atmosphere covered from light. Fluorescence was measured with a fluorescence microscope with excitation and emission wavelengths of 485 nm and 528 nm, respectively. Treatments were added at a volume of 50 μL to each well, and measurements continued for 20 s per well. Images and videos were obtained during the addition of the treatment, except in the case of the AEA pretreatment for 15 min and 3 h, where images were obtained only during the addition of 3NP + QUIN. 3NP [2.5 mM] and QUIN [250 µM] were used to quantify calcium mobilization. Fluorescence intensity of Fluo4-AM was quantified for each image and the background value subtracted.
PPARγ Transcriptional Assays
To study PPARγ transcriptional activity in the presence of AEA and neurotoxins, prior to seeding, cortical neurons were co-nucleofected with the GAL4-PPARγ construct and the luciferase reporter vector GAL4-luc using the Mouse Neuron Nucleofector Kit (Lonza, Cat No:VPG-1001) following the manufacturer's instructions, at a concentration of 3 μg of plasmid per each 3x106cells, and seeded in 24-well plates at a density of 200,000 cells/cm2 in neurobasal medium supplemented with 2% B-27. After 48 h, cells were treated with vehicle (DMSO), 1 µM pioglitazone (PIO) as a positive control for PPARγ activation, 100 nM AEA and 200 nM AEA for 5 h, and 3NP + QUIN for an additional 6 h. At the end of treatments, cell extracts were collected in 20 µl of passive lysis buffer per well. To determine luciferase activity as a reporter protein for PPARγ transcriptional activity, the extracts were analyzed in a 96-well white plate, using the Dual-Luciferase Reporter System (Promega, Madison, WI, USA) kit [35]. Plates were quantified in the FLUOstar® Omega multimode microplate reader; substrates were added using the microplate reader injectors and data were normalized by total protein content. PPARγ transcriptional activity is expressed as the change in relative light units/µg of protein compared to luciferase alone.
Statistical Analysis
Data are reported as mean values ± SD of n = 3 independent experiments per group, with 3 repeats per experiment. All results were statistically analyzed by one-way analysis of variance (ANOVA) for repeated measures. Differences between groups were assessed by Bonferroni’s multiple comparisons’ test. Values of p ≤ 0.05 were considered of statistical significance. Analytical procedures were performed using the scientific statistic software GraphPad Prism 8 (GraphPad Scientific, San Diego, CA, USA).
Results
AEA-Induced Neuroprotection Against Energy Deficiency and Excitotoxicity Relies on PPARγ and CB1 Receptors Activation
To evaluate the toxicity of 3NP and QUIN alone and when added together, cortical primary neurons were treated with increased concentrations of each neurotoxin. After 0.5 mM 3NP + 50 μM QUIN co-treatment, viability was reduced to a greater extent than when administered separately, suggesting an additive effect on their toxicity (Fig. 1A). Neurons were pretreated with increased concentrations of AEA 6 h before injury, and concentration–response characterization showed that AEA 100 nM was the optimal concentration to evoke neuroprotective effects after 0.5 mM 3NP + 50 μM QUIN treatment for 24 h (Fig. 1B). When evaluating AEA protection against 3NP or QUIN toxicity separately, we observed that AEA prevented only 3NP damage. In turn, QUIN alone had no effect on reducing cell viability, while AEA prevented again the combined toxic effect of 3NP + QUIN (Fig. 1C). Both the PPARγ antagonist GW9662 and the CB1 receptor antagonist SR141716 reverted the effect of AEA in preventing the reduction of cell viability induced by 3NP + QUIN, suggesting that both nuclear and plasma membrane receptors contribute to the neuroprotective effects mediated by AEA (Fig. 2A). AEA alone had no effect on cell viability.
Co-treatment of neuronal cells with 3NP + QUIN also decreased total ATP levels by 40% compared to the control group, while AEA partially attenuated this effect, resulting in a significant recovery compared to the 3NP + QUIN treatment group (Fig. 2B). Notably, the treatment of cells with AEA alone decreased ATP levels by about 20% compared to the control group. Lipid peroxidation, assessed using the TBARS assay, showed that 3NP + QUIN treatment increased TBARS signal by 2.5-fold compared to the control group, and this effect was attenuated in the presence of AEA compared to the 3NP + QUIN group by 45% (Fig. 2C), thus confirming its antioxidant capacity [25].
AEA Increases Mitochondrial Biogenesis and Mass
Mitochondrial DNA copy number (mitDNAcn) was assessed by quantitative real-time PCR (qPCR) as an indicator of mitochondrial mass (Fig. 3A). While AEA alone increased mitDNAcn by almost two-fold, the 3NP + QUIN condition decreased it by about 50%. Neurons pretreated with AEA and subsequently exposed to 3NP + QUIN exhibited a significant increase in mitochondrial mass, approximately threefold higher than that observed in cells treated with 3NP + QUIN alone. Treatment with SR141716, but not with GW9662, prevented the AEA-induced increase in mitDNAcn by around 150%, suggesting the involvement of the CB1 receptor in the effect of AEA.
The relative expression of TFAM and PPARGC1A genes (the latter coding for PGC1-α) was quantified by qPCR (Figs. 3B and 3 C, respectively). While the combination of 3NP + QUIN inhibited the TFAM and PGC-1α expression by 90% and 60% compared to the control group, respectively (Fig. 3B-C), neurons pretreated with AEA increased the TFAM expression and prevented the decrease in PGC-1α expression. Both GW9662 and SR141716 attenuated the effect of AEA on TFAM expression in neurons exposed to 3NP + QUIN (Fig. 3B), suggesting that CB1 and PPARγ receptors are involved in the AEA-induced mitochondrial biogenesis pathway. GW9662 moderately inhibited the effect of AEA on PGC-1α expression in neurons treated with 3NP + QUIN, whereas SR141716 exerted a stronger inhibitory effect on AEA-induced responses, suggesting differential regulatory roles of PPARγ and CB1 receptors in this context (Fig. 3C).
The voltage-dependent anion channel (VDAC), a protein located in the outer mitochondrial membrane, is involved in the regulation of mitochondrial function and neuronal energy metabolism by regulating the exchange of ions and metabolites between mitochondria and cytosol. While treatment with 3NP + QUIN led to a moderate increase in VDAC expression (~ 30%), pretreatment with AEA resulted in a substantially greater upregulation, with VDAC levels nearly threefold higher (Figs. 3D). AEA alone did not modify the basal levels of VDAC expression. These results suggest that a compensatory upregulation of mitochondrial mass induced by toxin-induced mitochondria dysfunction is primed by the presence of AEA. Although this may indicate an increase in protein regulation, it could also be aimed at restoring mitochondrial function in response to underlying dysfunction [36].
To characterize in more detail the increase in mitochondrial mass, fluorescent detection was carried out using MitoTracker Red CMXRos [32]. While the 3NP + QUIN condition decreased Mitotracker signal compared to the control group (25%), neurons pretreated with AEA induced a recovery in the staining signal compared to the 3NP + QUIN group (Fig. 3E). Collectively, these findings suggest that AEA promotes mitochondrial biogenesis pathways to enhance mitochondrial mass, which may contribute to mitigating the damage induced by 3NP + QUIN.
AEA Induces Regulation of Mitochondrial Morphology and Dynamics
ATPβ, also known as the beta subunit of ATP synthase, frequently used to study mitochondrial morphology due to its specific location within the inner mitochondrial membrane, was detected by immunofluorescence to assess mitochondrial morphology [37, 38]. Quantification of ATPβ fluorescence intensity revealed no significant changes in response to either AEA or 3NP + QUIN treatments alone when compared to the control group. In contrast, combined treatment with AEA and 3NP + QUIN resulted in a significant 75% increase in ATPβ levels (data not shown). Further morphological assessment of neurons comprised fluorescent staining and threshold of ATPβ (Figs. 4A).
Mitochondrial branching is important for the efficient distribution of proteins within the network, and a larger number of branches and junctions allows more efficient network connectivity. Although no changes were detected in mitochondrial area of neurons exposed to the different treatments (Fig. 3B), morphological analysis using the FIJI mitochondria analyzer plugin showed decreased mitochondrial perimeter by 50%, number of branches (70%) and branch junctions (50%), and an increase in mitochondrial compactness (50%) (Figs. 4C-4G) in neurons treated with 3NP + QUIN compared to the control group. In contrast, neurons pretreated with AEA and subsequently exposed to 3NP + QUIN exhibited a restoration across all assessed mitochondrial morphological parameters relative to the 3NP + QUIN group (Figs. 4B-4G). These results suggest that AEA induced network remodeling in the presence of toxic insults.
AEA Increases the Expression of Genes Associated with Mitochondrial Dynamics
To determine the participation of AEA in the regulation of mitochondrial dynamics, the relative expression of OPA1 gene (which participates in mitochondrial fusion) and DNM1L gene (coding for DRP1, involved in mitochondrial fission) was quantified by qPCR and normalized against actin as a housekeeping gene using the 2^(-ΔΔCt) method (Figs. 4H, I, respectively). While the 3NP + QUIN group did not show significant changes in the expression of these genes compared to the control group (Figs. 4H, I), pretreatment with AEA in neurons exposed to 3NP + QUIN led to a significant, approximately twofold increase in OPA1 expression (Fig. 4H). Notably, while both GW9662 and SR141716 reversed the effects of AEA on OPA expression in neurons exposed to 3NP + QUIN (Fig. 4H), SR141716 disproportionately decreased DRP1 expression in AEA plus 3NP + QUIN treated cells (Fig. 4I), which in turn might suggest a more prominent role of CB1 than PPARγ. AEA alone did not affect these endpoints. These results suggest that AEA is involved in the regulation of mitochondrial dynamics at the fusion level, supporting an active role of DRP1 and OPA1 in several physiological processes [39–41].
AEA Delays the Increase in Calcium Levels and Preserves Mitochondrial Membrane Potential
Cortical neurons were loaded with Fluo4-AM and treated with 3NP + QUIN and AEA to investigate the role of intracellular Ca2+ levels in neurotoxicity (Fig. 5A-5B). Cortical neurons responded immediately with increased intracellular calcium levels upon the addition of calcimycin [1 µM], a calcium ionophore used as a positive control. Treatment with 3NP + QUIN also increased intracellular calcium but in a slower manner. Pretreatment for 3 h with AEA in part decreased the toxin-induced calcium increase levels. Intracellular calcium level dynamics are shown as additional videos in Supplementary Fig. 1 (Figure S1).
Mitochondrial membrane potential (ΔΨM, MMP) is a key indicator of proper mitochondrial function, and its alteration represents a key marker of impaired mitochondrial function [42, 43]. We used DiSC3(5) as a fluorescent cationic dye to measure ΔΨM (Fig. 5C). AEA alone slightly decreased MMP. As expected, the 3NP + QUIN treatment led to a consistent reduction in mitochondrial membrane potential (ΔΨM) compared to the control group. In contrast, pretreatment of neurons with (AEA) prior to 3NP + QUIN exposure effectively restored ΔΨM to baseline levels.
AEA Preserves Oxygen Consumption in Neurons Exposed to Toxic Insults
To evaluate changes in cellular energy metabolism, oxygen consumption rate (OCR) was assessed as an indicator of mitochondrial respiration, and the extracellular acidification rate (ECAR) was assessed as an indicator of glycolysis (Fig. 6), after 30 min or 24 h of toxins exposure. Treatment with toxins for 30 min did not induce changes in either OCR or ECAR (data not shown). In turn, OCR analysis after 24 h of toxins exposure (Fig. 6A) revealed that 3NP + QUIN induced a decrease in basal respiration (Fig. 6B), maximal respiration (Fig. 6C), spare respiratory capacity (Fig. 6D), and ATP production (Fig. 6E) compared to the control group. In contrast, cells pretreated for six hours with AEA exhibited significant recovery in basal respiration, maximal respiratory capacity, and ATP production compared to neurons treated with 3NP + QUIN alone (Figs. 6B, 6 C and 6E). AEA alone did not affect the basal mitochondrial functions. These data suggest that AEA may boost neuronal oxidative metabolism in the presence of neurodegenerative insults.
The ECAR data at 24 h (Fig. 6F) showed that the insult induced by 3NP + QUIN decreased basal glycolysis (Fig. 6G) and compensatory glycolysis (Fig. 6H) compared to the control group. Pretreatment of neuronal cells exposed to 3NP + QUIN with anandamide (AEA) fully restored these two endpoints relative to the group receiving the neurodegenerative insult alone (Figs. 6F, 6G, and 6H). Treatment with AEA alone did not significantly alter these endpoints compared to the control group.
Discussion
ECB signaling exerts neuroprotective functions via multiple receptor pathways, highlighting its multitarget potential and unveiling complex mechanisms involved in pathological neuronal signaling. Cell viability assays, quantification of MTT reduction, and ATP levels showed that the 3NP + QUIN insult induces neuronal damage, interfering with mitochondrial metabolic activity. Results derived from the lipid peroxidation assay further implicate oxidative stress as a contributing factor of neurodegeneration, and that AEA attenuates this toxicity mechanism. QUIN induced neurodegeneration is mediated by the overactivation of NMDA receptors, resulting in enhanced calcium levels, energy deficit, oxidative stress and cell death [44]. In turn, the main toxic mechanism evoked by 3NP involves its intracellular incorporation into mitochondria and the inhibition of energy production, which can lead to ATP depletion while enhancing excitotoxicity [45, 46]. In addition, 3NP has been reported to increase intracellular calcium levels through NMDA receptor activation, thus contributing to cell damage [47]. Thus, the combined neurodegeneration induced by 3NP and QUIN co-treatment integrates mitochondrial dysfunction with excitotoxicity, generating a model of neurodegeneration characterized by significant decrease of cell viability that surpasses the effects of each toxin alone. Here, we demonstrate that AEA delayed the toxin-mediated intracellular Ca2+ levels during the early phase of exposure, thus preserving cellular homeostasis.
Treatment with AEA prevented both oxidative damage and the decreased viability in neurons at a concentration of 100 nM, in line with previous reports showing that AEA, at nanomolar concentrations, prevents neurodegeneration and hypoxic injury in a CB1 receptor dependent manner [48, 49]. Alternatively, high concentrations of AEA can be deleterious to neuronal survival in agreement with the classical biphasic actions of cannabinoids.
We observed that the antagonists GW9662 and SR141716, inhibited AEA neuroprotection, indicating that both PPARγ and CB1 receptors mediate the protective effects of this EC. Due to its lipophilic nature, AEA can readily diffuse across cell membrane to reach PPARγ receptors, and mitochondrial CB1 receptors (mitCB1). Notably, PPARγ receptor activity can result from direct interaction with cannabinoids, indirectly driven from membrane CB1 receptor signaling or from PPARγ interaction with AEA-derived metabolites [50]. Further supporting these concepts, our study provides evidence that AEA induces PPARγ transactivation under neurodegenerative conditions.
The decrease in mitDNAcn and mitotracker fluorescence in neurons exposed to the toxins, and their prevention by AEA, suggest that the neuroprotective effect of AEA is associated with increased mitochondrial mass. VDAC regulates mitochondrial function and neuronal energy metabolism [36]. Also, AEA increased VDAC expression in neurons treated with 3NP + QUIN, but not under control conditions, suggesting that AEA promotes the compensatory upregulation of mitochondrial biogenesis and function in response to mitochondrial dysfunction.
PGC1-α, the coactivator of the PPARγ receptor, is key for the induction of mitochondrial biogenesis by promoting the transcription of genes such as TFAM. Assessment by qPCR indicated that AEA increased the expression of genes encoding PGC1-α and TFAM proteins, and this effect was prevented by GW9662, thus linking the increase in mitochondrial mass to a PPARγ-dependent mitochondrial biogenesis mechanism. CB1 antagonism promoted a greater downregulation of mitDNA and the PPARGC1A gene that encodes the protein PGC1-α, than PPARγ antagonism, suggesting a prominent role of the CB1 receptor in AEA-induced mitochondrial biogenesis. This is consistent with studies showing the ability of CB1 to promote mitDNA and PGC-1α expression via CB1 [19], whereas Δ9-THCA, a double CB1 and PPARγ agonist efficiently upregulates PGC-1α expression [51]. Furthermore, corroborating earlier findings showing that CB1 signaling induces PPARγ transactivation [52, 53], our results also confirmed that the regulation of PPARγ by CB1 activity was associated with regulation of mitochondrial biogenesis induced by AEA.
Balanced mitochondrial fission and fusion dynamics are critical for maintaining mitochondrial bioenergetics and synaptic integrity in neurons. Inhibition of Drp1, a key mediator of mitochondrial fission, confers neuroprotective effects in both in vitro and in vivo models. An imbalance favoring excessive fission is frequently associated with neuronal degeneration observed in neurodegenerative diseases [54]. In contrast, OPA1 is an essential GTPase responsible for mitochondrial inner membrane fusion. Adenoviral mediated expression of OPA1 has been shown to restore in vitro mitochondrial function [55], while its deficiency hastens age-related deficits in learning and memory [56]. Mitochondrial fusion plays a protective role against neuronal stress by enabling the redistribution of mitochondrial contents and facilitating the exchange of mitochondrial components. This process supports cellular homeostasis, preserves mitochondrial function, and contributes to the delay of apoptotic signaling [57, 58]. Here we observed an increase in OPA1 gene expression in AEA-treated neurons exposed to 3NP + QUIN, and no significant change in DRP1 gene expression in neurons under the same conditions, suggesting that the neuroprotective effect of AEA is more dependent on mitochondrial fusion. The increase in OPA1 expression induced by AEA was inhibited by the PPARγ antagonist, but not by the CB1 antagonist, indicating the participation of PPARγ in the regulation of AEA-induced OPA1 transcription in a CB1-independent manner.
Although mitochondrial morphology in neurons exhibits substantial variability across subcellular compartments, namely the soma, dendrites, and axons [59], morphological alterations typically result from changes in fission, fusion rates and mitochondrial membrane potential. AEA pretreatment decreased mitochondrial compactness, while increasing the number of branches and branch junctions. The increase in branches after AEA pretreatment is consistent with increased fusion and the ability of mitochondria to generate elongated branched network. We hypothesize that the lack of significant changes in mitochondrial number may be due to increased fusion. Mitochondrial compaction in the soma also decreased with AEA pretreatment, suggesting decreased death signaling [60].
Mitochondrial membrane potential (ΔΨm) is a key indicator of respiratory chain deficits, proton leak due to membrane damage, or enhanced activation of the mitochondrial permeability transition pore (mPTP) [61]. 3NP + QUIN treatment led to decreased ΔΨm, OCR and ECAR. Pretreatment with AEA partially attenuated the decline in ΔΨm and OCR, while significantly enhancing ECAR compared to the control group, 24 h after injury. These findings align with previous reports demonstrating that antioxidant compounds can mitigate mitochondrial damage induced by 3NP and QUIN. Such protective effects are thought to be mediated through the activation of endogenous antioxidant pathways, particularly the Nrf2/ARE signaling axis, in addition to their direct capacity to neutralize reactive oxygen species as free radical scavengers [62, 63], and these mechanisms were also inherent to AEA treatment [25].
Neurons have limited metabolic flexibility, relying primarily on oxidative phosphorylation (OXPHO) for ATP production and utilizing lactate supplied by astrocytes as an additional energy source [64]. Nonetheless, neurons can positively regulate glycolysis even when experiencing mitochondrial respiration stress [65]. ECAR is the value of the extracellular lactic acid production rate, which correlates with glycolysis. AEA significantly increased the neuronal ECAR rate following 24 h of exposure to neurodegenerative stimuli. Furthermore, a marked peak in ECAR was detected upon administration of oligomycin, an inhibitor of mitochondrial ATP synthase, indicating a shift toward glycolytic compensation. These findings suggest that AEA promotes an adaptive metabolic response in neurons, potentially enhancing cellular resilience under conditions of mitochondrial dysfunction. Notably, neurons treated with toxins without AEA did not show an increase in ECAR. Thus, the observed effects support a role for AEA as a modulator of the metabolic shift under pathological conditions. This ability to influence cellular energy reprogramming positions AEA as a promising candidate for further investigation in the context of neurodegenerative disease and mitochondrial dysfunction.
We have also observed that AEA alone, in healthy neurons, produced metabolic and mitochondrial alterations, such as decreased ATP, decreased ΔΨm and oxygen consumption. This observation suggests that the neuroprotective effects of AEA may be conditional, manifesting primarily under stress- or damage-induced states, while eliciting distinct responses in neurons under basal conditions. Such context-dependent effects are particularly relevant given the differential expression patterns of cannabinoid receptors observed in pathological versus physiological states. The reduction of mitochondrial activity, membrane potential and ATP production may be explained by direct binding of AEA to FoF1 ATP synthase inhibiting this activity but not the hydrolase activity [66]. It has also been reported that AEA decreases the mitochondrial membrane potential while increasing the fluidity of the outer mitochondrial membrane at micromolar concentrations when directly incorporates to membrane [67]. Furthermore, mtCB1 activation has been shown to decrease complex I activity, oxygen consumption, and ATP levels; however, these effects of AEA on mitochondria do not promote neuronal death mechanisms [68–70], thus suggesting that they remain at a regulatory level, not at a toxic level. In this context, investigating the role of mitochondrial CB1 receptors (mtCB1) in mediating the AEA-induced effects reported here warrants particular attention.
Conclusion
Collectively, our novel findings demonstrate that anandamide AEA confers neuroprotection via activation of CB1 receptors and the induction of PPARγ-mediated transcriptional pathways. These effects were associated with increased mitochondrial biogenesis and enhanced mitochondrial function, thereby supporting neuronal metabolic activity and viability. The combined neurodegenerative insult of 3NP and QUIN employed in this model significantly reduced cell viability and elevated oxidative stress markers, effectively recapitulating key metabolic, mitochondrial, and morphological disturbances characteristic of neurodegenerative diseases. These findings contribute to elucidating the diversity of neuroprotective mechanisms induced by the ECS and hence of relevance for neurodegenerative diseases.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
This paper is part of the requirements for Ana Laura Torres-Román to obtain a doctoral degree at the Posgrado en Ciencias Biológicas, UNAM (Mexico). We would like to thank Drs. Teresa I. Fortoul-Van Der Goes and Julio Morán-Andrade (UNAM), and Manuel Guzmán and Noemi Esteras (UCM), for their constructive input to the project andexperimental support. We also thank the “Consejo Nacional de Humanidades, Ciencias y Tecnologías” (CONAHCyT), which has become the “Secretaría de Ciencia, Humanidades, Tecnología e Innovación” (SECIHTI) of Mexico for funding this research through a full scholarship given to Ana Laura Torres-Román.
Funding
Open access funding provided by Universidad Autonoma Metropolitana (BIDIUAM) This project was funded by the Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCyT, Mexico), which has now become the Secretaría de Ciencias, Humanidades, Tecnología e Innovación (SECIHTI), by grant number 809272 given to Ana Laura Torres-Román, as well as by the Programa de Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, the CannaLatan network (CYTED #220RT0002) to A.L.T.-R. and I.G.-R., and PI21/0938 Instituto de Salud Carlos III to I.G-R. Grant IN202725 from PAPPIT (DGAPA, UNAM) was given to J.P.-C. None of the sponsors were involved in design, collection, analysis or interpretation of data, or in writing reports or decisions to submit the article for publication.
Data Availability
The data that support the findings of this review are available from the corresponding author upon reasonable request.
Declarations
Ethics Approval
This project was evaluated and validated by the Evaluation Committee of the Programa de Posgrado en Ciencias Biológicas (Postgraduate Program in Biological Sciences), Universidad Nacional Autónoma de México (UNAM). Experimental procedures were performed in accordance with the guidelines and approval of the Animal Welfare Committees of Universidad Complutense de Madrid, Comunidad de Madrid, the directives of the Spanish Government and the European Commission (RD 118/2021). Animal research authorization number PROEX135/23.
Conflict of interests
The authors declare no competing interests.
Footnotes
Footnote Group
Contributor Information
Ismael Galve-Roperh, Email: igalvero@ucm.es.
Abel Santamaría, Email: absada@yahoo.com.
References
Untitled section
References
- 1.Klemmensen MM, Borrowman SH, Pearce C et al (2024) Mitochondrial dysfunction in neurodegenerative disorders. Neurotherapeutics 21:e00292. 10.1016/j.neurot.2023.10.002
- 2.Paiva BS, Neves D, Tomé D et al (2025) Neuroprotection by mitochondrial NAD against glutamate-induced excitotoxicity. Cells. 10.3390/cells14080582
- 3.Neves D, Salazar IL, Almeida RD, Silva RM (2023) Molecular mechanisms of ischemia and glutamate excitotoxicity. Life Sci 328:121814. 10.1016/j.lfs.2023.121814
- 4.Aklima J, Onchaiya S, Saotome T et al (2022) Direct analysis of mitochondrial damage caused by misfolded/destabilized proteins. Int J Mol Sci 23:9881. 10.3390/ijms23179881
- 5.Seager R, Lee L, Henley JM, Wilkinson KA (2020) Mechanisms and roles of mitochondrial localisation and dynamics in neuronal function. Neuronal Signal. 10.1042/NS20200008
- 6.Neueder A, Kojer K, Gu Z et al (2024) Huntington’s disease affects mitochondrial network dynamics predisposing to pathogenic mitochondrial DNA mutations. Brain 147:2009–2022. 10.1093/brain/awae007
- 7.Keskinoz EN, Celik M, Toklucu ES et al (2024) Mitochondrial alterations in Alzheimer’s disease: insight from the 5xFAD mouse model. Mol Neurobiol. 10.1007/s12035-024-04632-4
- 8.Jamwal S, Blackburn JK, Elsworth JD (2021) PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Ther 219:107705. 10.1016/j.pharmthera.2020.107705
- 9.Dabrowska A, Venero JL, Iwasawa R et al (2015) PGC-1α controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. Aging 7:629–643. 10.18632/aging.100790
- 10.Katsouri L, Parr C, Bogdanovic N et al (2011) PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. J Alzheimers Dis 25:151–162. 10.3233/JAD-2011-101356
- 11.Priya D, Hani U, Haider N, Talath S, Shanmugarajan D, Prabitha P, Archana P, Prashantha Kumar BR (2024) Novel PPAR-γ agonists as potential neuroprotective agents against Alzheimer’s disease: rational design, synthesis, in silico evaluation, PPAR-γ binding assay and transactivation and expression studies. RSC Adv 14:33247–33266. 10.1039/D4RA06330A
- 12.Chandra A, Sharma A, Calingasan NY et al (2016) Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington’s disease. Hum Mol Genet 25:2269–2282. 10.1093/hmg/ddw095
- 13.Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M (2008) Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 14:2279–2288. 10.2174/138161208785740117
- 14.Thapa S, Singh SK (2023) The role of endocannabinoid system in neuroprotection: molecular targets and therapeutic opportunities. Integr Med Rep 2:72–86. 10.1089/imr.2022.0091
- 15.Khosropoor S, Alavi MS, Etemad L, Roohbakhsh A (2023) Cannabidiol goes nuclear: the role of PPARγ. Phytomedicine 114:154771. 10.1016/j.phymed.2023.154771
- 16.Reyes-Soto CY, Villaseca-Flores M, Ovalle-Noguez EA, Nava-Osorio J, Galván-Arzate S, Rangel-López E, Santamaría A (2022) Oleamide reduces mitochondrial dysfunction and toxicity in rat cortical slices through the combined action of cannabinoid receptors activation and induction of antioxidant activity. Neurotox Res 40(6):2167–2178. 10.1007/s12640-022-00575-7
- 17.Liang Z, Soriano-Castell D, Kepchia D, Duggan BM, Currais A, Schubert D, Maher P (2022) Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors. Free Radic Biol Med 180:33–51. 10.1016/j.freeradbiomed.2022.01.001
- 18.Zeissler ML, Eastwood J, McCorry K, Hanemann CO, Zajicek JP, Carroll CB (2016) Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget 7(29):46603. 10.18632/oncotarget.10314
- 19.Sun S, Jiang T, Duan N et al (2021) Activation of CB1R-dependent PGC-1α is involved in the improved mitochondrial biogenesis induced by electroacupuncture pretreatment. Rejuvenation Res 24:104–119. 10.1089/rej.2020.2315
- 20.Xu Z, Lv X-A, Dai Q et al (2016) Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and its role in metabolic defects and neuronal apoptosis after TBI. Mol Brain 9:75. 10.1186/s13041-016-0257-8
- 21.Yang S, Hu B, Wang Z et al (2020) Cannabinoid CB1 receptor agonist ACEA alleviates brain ischemia/reperfusion injury via CB1–Drp1 pathway. Cell Death Discov 6:102. 10.1038/s41420-020-00338-3
- 22.Ma L, Jia J, Niu W et al (2015) Mitochondrial CB1 receptor is involved in ACEA-induced protective effects on neurons and mitochondrial functions. Sci Rep 5:12440. 10.1038/srep12440
- 23.Malheiro RF, Carmo H, Carvalho F, Silva JP (2023) Cannabinoid-mediated targeting of mitochondria on the modulation of mitochondrial function and dynamics. Pharmacol Res 187:106603. 10.1016/j.phrs.2022.106603
- 24.Bouaboula M, Hilairet S, Marchand J et al (2005) Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517:174–181. 10.1016/j.ejphar.2005.05.032
- 25.Maya-López M, Monsalvo-Maraver LA, Delgado-Arzate AL et al (2024) Anandamide and WIN 55212–2 afford protection in rat brain mitochondria in a toxic model induced by 3-nitropropionic acid: an in vitro study. Mol Neurobiol 61:6435–6452. 10.1007/s12035-024-03967-2
- 26.Santamaría A, Galván-Arzate S, Lisý V et al (2001) Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 12:871–874. 10.1097/00001756-200103260-00049
- 27.Hestad K, Alexander J, Rootwelt H, Aaseth JO (2022) The role of tryptophan dysmetabolism and quinolinic acid in depressive and neurodegenerative diseases. Biomolecules. 10.3390/biom12070998
- 28.Kaur P, Attri S, Singh D et al (2023) Neuromodulatory effect of 4-(methylthio)butyl isothiocyanate against 3-nitropropionic acid induced oxidative impairments in human dopaminergic SH-SY5Y cells via BDNF/CREB/TrkB pathway. Sci Rep 13:4461. 10.1038/s41598-023-31716-3
- 29.Reyes-Soto CY, Rangel-López E, Galván-Arzate S et al (2020) S-allylcysteine protects against excitotoxic damage in rat cortical slices via reduction of oxidative damage, activation of Nrf2/ARE binding, and BDNF preservation. Neurotox Res 38:929–940. 10.1007/s12640-020-00260-7
- 30.Kotlar I, Rangel-López E, Colonnello A et al (2019) Anandamide reduces the toxic synergism exerted by quinolinic acid and glutaric acid in rat brain neuronal cells. Neuroscience 401:84–95. 10.1016/j.neuroscience.2019.01.014
- 31.Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72(1–2):248–254. 10.1016/0003-2697(76)90527-3
- 32.Neikirk K, Marshall AG, Kula B et al (2023) MitoTracker: a useful tool in need of better alternatives. Eur J Cell Biol 102:151371. 10.1016/j.ejcb.2023.151371
- 33.Kinjo T, Ashida Y, Higashi H et al (2018) Alleviation by GABAB receptors of neurotoxicity mediated by mitochondrial permeability transition pore in cultured murine cortical neurons exposed to N-methyl-d-aspartate. Neurochem Res 43:79–88. 10.1007/s11064-017-2311-z
- 34.McKenzie M, Lim SC et al (2017) Simultaneous measurement of mitochondrial calcium and mitochondrial membrane potential in live cells by fluorescent microscopy. Journal of visualized experiments: JoVE 119:55166. 10.3791/55166
- 35.Díaz-Alonso J, Paraíso-Luna et al (2016) VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease. Sci Rep 6, 29789. 10.1038/srep29789
- 36.He Y, Wang W, Yang T et al (2022) The potential role of voltage-dependent anion channel in the treatment of Parkinson’s disease. Oxid Med Cell Longev 2022:1–13. 10.1155/2022/4665530
- 37.Guan D, Liang C, Zheng D et al (2025) The role of mitochondrial remodeling in neurodegenerative diseases. Neurochem Int 183:105927. 10.1016/j.neuint.2024.105927
- 38.Fogo GM, Anzell AR, Maheras KJ et al (2021) Machine learning-based classification of mitochondrial morphology in primary neurons and brain. Sci Rep 11:5133. 10.1038/s41598-021-84528-8
- 39.Schuler M-H, Hughes AL (2020) OPA1 and angiogenesis: beyond the fusion function. Cell Metab 31:886–887. 10.1016/j.cmet.2020.04.014
- 40.Kushnareva YE, Gerencser AA, Bossy B et al (2013) Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity. Cell Death Differ 20:353–365. 10.1038/cdd.2012.128
- 41.Fan RZ, Sportelli C, Lai Y et al (2024) A partial Drp1 knockout improves autophagy flux independent of mitochondrial function. Mol Neurodegeneration 19:26. 10.1186/s13024-024-00708-w
- 42.Amo T, Sato S, Saiki S et al (2011) Mitochondrial membrane potential decrease caused by loss of PINK1 is not due to proton leak, but to respiratory chain defects. Neurobiol Dis 41(1):111–118. 10.1016/j.nbd.2010.08.027
- 43.Rehfeldt SCH, Laufer S, Goettert MI (2021) A highly selective in vitro JNK3 inhibitor, FMU200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in SH-SY5Y cells. Int J Mol Sci 22:3701. 10.3390/ijms22073701
- 44.Pérez-De La Cruz V, Carrillo-Mora P, Santamaría A (2012) Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 5:1–8. 10.4137/IJTR.S8158
- 45.Zhou X, Hollern D, Liao J et al (2013) NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis 4:e560–e560. 10.1038/cddis.2013.82
- 46.Upadhayay S, Yedke NG, Rahi V et al (2023) An overview of the pathophysiological mechanisms of 3-nitropropionic acid (3-NPA) as a neurotoxin in a Huntington’s disease model and its relevance to drug discovery and development. Neurochem Res 48:1631–1647. 10.1007/s11064-023-03868-1
- 47.Nasr P, Gursahani HI, Pang Z, Bondada V, Lee J, Hadley RW, Geddes JW (2003) Influence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochem Int 43(2):89–99. 10.1016/S0197-0186(02)00229-2
- 48.Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278:157–160. 10.1016/S0304-3940(99)00922-2
- 49.Milton NGN (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide. Neurosci Lett 332:127–130. 10.1016/S0304-3940(02)00936-9
- 50.Lago-Fernandez A, Zarzo-Arias S, Jagerovic N, Morales P (2021) Relevance of peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system. Int J Mol Sci 22:1001. 10.3390/ijms22031001
- 51.Nadal X, Del Río C, Casano S, Palomares B, Ferreiro-Vera C, Navarrete C, Muñoz E (2017) Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. Br J Pharmacol 174(23):4263–4276. 10.1111/bph.14019
- 52.Iannotti FA, Vitale RM (2021) The endocannabinoid system and PPARs: focus on their signalling crosstalk, action and transcriptional regulation. Cells 10:586. 10.3390/cells10030586
- 53.O’Sullivan SE (2016) An update on PPAR activation by cannabinoids. Br J Pharmacol 173:1899–1910. 10.1111/bph.13497
- 54.Grohm J, Kim SW, Mamrak U, Tobaben S, Cassidy-Stone A, Nunnari J, Culmsee C (2012) Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ 19(9):1446–1458. 10.1038/cdd.2012.18
- 55.Maloney DM, Chadderton N, Millington-Ward S et al (2020) Optimized OPA1 isoforms 1 and 7 provide therapeutic benefit in models of mitochondrial dysfunction. Front Neurosci. 10.3389/fnins.2020.571479
- 56.Bevan RJ, Williams PA, Waters CT et al (2020) OPA1 deficiency accelerates hippocampal synaptic remodelling and age-related deficits in learning and memory. Brain Commun. 10.1093/braincomms/fcaa101
- 57.Chen H, McCaffery JM, Chan DC (2007) Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130:548–562. 10.1016/j.cell.2007.06.026
- 58.Kochan SMV, Malo MC, Jevtic M et al (2024) Enhanced mitochondrial fusion during a critical period of synaptic plasticity in adult-born neurons. Neuron 112:1997-2014.e6. 10.1016/j.neuron.2024.03.013
- 59.Faitg J, Lacefield C, Davey T et al (2021) 3D neuronal mitochondrial morphology in axons, dendrites, and somata of the aging mouse hippocampus. Cell Rep 36:109509. 10.1016/j.celrep.2021.109509
- 60.Misgeld T, Schwarz TL (2017) Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96(3):651–666. 10.1016/j.neuron.2017.09.055
- 61.Rottenberg H (2023) The reduction in the mitochondrial membrane potential in aging: the role of the mitochondrial permeability transition pore. Int J Mol Sci. 10.3390/ijms241512295
- 62.Luis-García ER, Limón-Pacheco JH, Serrano-García N et al (2017) Sulforaphane prevents quinolinic acid-induced mitochondrial dysfunction in rat striatum. J Biochem Mol Toxicol. 10.1002/jbt.21837
- 63.Drummond NJ, Davies NO, Lovett JE et al (2017) A synthetic cell permeable antioxidant protects neurons against acute oxidative stress. Sci Rep 7:11857. 10.1038/s41598-017-12072-5
- 64.Almeida A, Jimenez-Blasco D, Bolaños JP (2023) Cross-talk between energy and redox metabolism in astrocyte-neuron functional cooperation. Essays Biochem 67:17–26. 10.1042/EBC20220075
- 65.Garcia S, Saldana-Caboverde A, Anwar M et al (2022) Enhanced glycolysis and GSK3 inactivation promote brain metabolic adaptations following neuronal mitochondrial stress. Hum Mol Genet 31:692–704. 10.1093/hmg/ddab282
- 66.Zaccagnino P, Corcelli A, Baronio M, Lorusso M (2011) Anandamide inhibits oxidative phosphorylation in isolated liver mitochondria. FEBS Lett 585:429–434. 10.1016/j.febslet.2010.12.032
- 67.Catanzaro G, Rapino C, Oddi S, Maccarrone M (2009) Anandamide increases swelling and reduces calcium sensitivity of mitochondria. Biochem Biophys Res Commun 388:439–442. 10.1016/j.bbrc.2009.08.037
- 68.Bénard G, Massa F, Puente N et al (2012) Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci 15:558–564. 10.1038/nn.3053
- 69.Melser S, Pagano Zottola AC, Serrat R, et al (2017) Functional Analysis of Mitochondrial CB1 Cannabinoid Receptors (mtCB1) in the Brain. Methods Enzymol 593:143-174. 10.1016/bs.mie.2017.06.023
- 70.Maya-López M, Zazueta C, Retana-Márquez S et al (2021) The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R). NeuroPsychopharmacotherapy. Springer International Publishing, Cham, pp 1–23
Associated Data
Supplementary Materials
Data Availability Statement
The data that support the findings of this review are available from the corresponding author upon reasonable request.